Seeking Alpha

Cyclacel Pharmaceuticals jumps on Janney initiation

  • Cyclacel Pharmaceuticals (CYCC) rises 5% premarket (on top of 10% in Monday's regular session) in what looks like a reaction to an initiation (Buy) at Janney Montgomery.
  • Price target is $10.
  • Bullish call is more than likely tied to the company's Phase 3 AML candidate sapacitabine.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector